Literature DB >> 1329931

Human B-lymphoid cell lines.

K Nilsson1.   

Abstract

The collective efforts during almost three decades by hematologists, tumor biologists and immunologists have provided a collection of established human hematopoietic cell lines, representing most of the hematopoietic cell lineages. The representativity of cell lines derived from the B cell differentiation lineage, however, is the most impressive. Human B-lymphoid cell lines are extensively used world wide as models in studies of various aspects of B cell biology and as tools in research on the etiology, pathogenesis and the biology of leukemia and lymphoma. Lymphoblastoid cell lines (LCL) carrying the Epstein-Barr Virus (EBV) are of particular importance. These lines can be established spontaneously from blood and lymphoid tissue from any EBV positive individual by special techniques, and from all individuals by EBV infection of peripheral blood B cells by EBV infection in vitro. At spontaneous establishment B cells, latently infected by EBV in vivo, will release EBV which subsequently infects normal EBV-negative B cells and immortalizes them into LCL cells, but direct outgrowth of the latently infected B cells as LCLs has also been documented. The target B cells for the EBV infection in vitro are not fully defined-most are mature B cells but also pro-B and pre-B and some B-blasts can be infected. Apart from their capacity for infinite growth, LCL cells have non-malignant properties, e. g. they are diploid, do not grow in agarose and do not form tumors upon inoculation subcutaneously in nude mice. LCLs have a phenotype corresponding to activated B cells (B-blasts) and have been used as "the E. Coli" of eukaryotic cells for about two decades. LCLs are derived at a high frequency also from tumor biopsies of EBV positive patients with leukemia and lymphoma. However, tumor cell lines are available from most of the B cell lineage-derived leukemias, B-lymphomas and myeloma. The frequency of successful establishment has been particularly high from EBV positive Burkitt's lymphoma (BL). From EBV genome negative BL and other B-lymphoma and B-leukemia biopsies the frequency of successful, spontaneous establishment is low (5-10%), and such lines have, with rare exceptions, been derived from pleural effusions and ascitis of patients with advanced, chemotherapy resistant, disease. Many of the cell lines therefore do not represent the clinically most common types of leukemia and lymphoma. No authentic malignant cell lines have been established from chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) and Waldenström's disease.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1329931

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  13 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Development of a robust method for establishing B cell lines using Epstein-Barr Virus.

Authors:  Inaho Danjoh; Hiyori Sone; Ryoko Shirota; Takashi Hiroyama; Yukio Nakamura
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

3.  At a crossroads: human DNA tumor viruses and the host DNA damage response.

Authors:  Pavel A Nikitin; Micah A Luftig
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

4.  Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Authors:  Christophe Le Clorennec; Tan-Sothéa Ouk; Ibtissam Youlyouz-Marfak; Stéphanie Panteix; Catherine-Claude Martin; Julia Rastelli; Eric Adriaenssens; Ursula Zimber-Strobl; Jean Coll; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

5.  Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.

Authors:  Gregory Kennedy; Jun Komano; Bill Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-05       Impact factor: 11.205

6.  The Sonoda-Tajima Cell Collection: a human genetics research resource with emphasis on South American indigenous populations.

Authors:  Inaho Danjoh; Kaoru Saijo; Takashi Hiroyama; Yukio Nakamura
Journal:  Genome Biol Evol       Date:  2011-03-07       Impact factor: 3.416

7.  Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines.

Authors:  Dong Hyeon Lee; Kyu Sang Park; In Deok Kong; Jun Woo Kim; Bok Ghee Han
Journal:  BMC Immunol       Date:  2006-09-14       Impact factor: 3.615

8.  VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.

Authors:  Ilaria Nichele; Alberto Zamò; Anna Bertolaso; Francesco Bifari; Martina Tinelli; Marta Franchini; Roberta Stradoni; Fiorenza Aprili; Giovanni Pizzolo; Mauro Krampera
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

Review 9.  Role of the ubiquitin system and tumor viruses in AIDS-related cancer.

Authors:  Julia Shackelford; Joseph S Pagano
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

10.  Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines.

Authors:  Koki Fujimori; Toshiki Tezuka; Hiroyuki Ishiura; Jun Mitsui; Koichiro Doi; Jun Yoshimura; Hirobumi Tada; Takuya Matsumoto; Miho Isoda; Ryota Hashimoto; Nubutaka Hattori; Takuya Takahashi; Shinichi Morishita; Shoji Tsuji; Wado Akamatsu; Hideyuki Okano
Journal:  Mol Brain       Date:  2016-10-03       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.